Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Trastuzumab Rezetecan is named as an intervention in 58 current clinical trials in our China register. 33 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Fudan University (12). The most-studied condition is Breast Cancer.

Trials by status

Recruiting3357%
Not yet open1831%
Active, closed712%

Trials by phase

Phase 23866%
Phase 31119%
Phase 1/2712%
Phase 112%
Phase 412%

Clinical trials of Trastuzumab Rezetecan

58 trials

Study	Phase	Status	Lead sponsor	Registers
Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer NCT07600164 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer, Advanced Breast Cancer	Phase 4	Recruiting	Peking University People's Hospital	China
A Study of SHR-A1811 in Subjects With Ovarian Cancer NCT06828354 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	China
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer NCT07111832 · ClinicalTrials.gov ↗ · PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy NCT07528716 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Fudan University	China
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer NCT07679360 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
Reverse Triple Negative Immune Resistant Breast Cancer NCT05076682 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 2	Recruiting	Fudan University	China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Breast Tumors	Phase 2	Recruiting	Fudan University	China
SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor	Phase 2	Recruiting	Fudan University	China
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients NCT05635487 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Recruiting	Shengjing Hospital	China
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer NCT06340230 · ClinicalTrials.gov ↗ · HR Positive/HER2 Low Breast Cancer	Phase 2	Recruiting	Shengjing Hospital	China
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer NCT06547736 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Fudan University	China
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer NCT06649331 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)	Phase 2	Recruiting	Fudan University	China
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer NCT06778031 · ClinicalTrials.gov ↗ · HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer	Phase 2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer NCT07051486 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Cervical Cancer	Phase 2	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	China
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases NCT07100600 · ClinicalTrials.gov ↗ · HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy	Phase 2	Recruiting	Henan Cancer Hospital	China
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma NCT07102901 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	China
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer NCT07110571 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal-junction Cancer	Phase 2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis NCT07203729 · ClinicalTrials.gov ↗ · HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) NCT07241793 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent	Phase 2	Recruiting	Sun Yat-sen University	China
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies NCT07309770 · ClinicalTrials.gov ↗ · Urachal Cancer, Advanced Solid Tumor Cancer, Antibody-drug Conjugates	Phase 2	Recruiting	Sheng Zhang	China
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer NCT07340398 · ClinicalTrials.gov ↗ · HER2-positive Early Breast Cancer	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer NCT07497386 · ClinicalTrials.gov ↗ · Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer	Phase 2	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	China
Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer NCT07647263 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Recruiting	The First Affiliated Hospital of Soochow University	China
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer NCT07670273 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Immunotherapy	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer NCT07704177 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Immunotherapy	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC NCT07741448 · ClinicalTrials.gov ↗ · UTUC	Phase 2	Recruiting	Zhiquan Hu	China
Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer NCT07817082 · ClinicalTrials.gov ↗ · Advanced Breast Cancer With Ultra-Low HER2 Expression	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer NCT06222879 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1/2	Recruiting	Shandong Suncadia Medicine Co., Ltd.	China
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis NCT06718933 · ClinicalTrials.gov ↗ · Breast Cancer Metastatic, Breast Cancer Brain Metastases	Phase 1/2	Recruiting	Fudan University	China
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer NCT06840002 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer NCT06859775 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Cervical Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor NCT07140393 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	China
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor NCT07275242 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer NCT06990503 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Not yet open	Tongji Hospital	China
Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype NCT07382687 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Not yet open	Fudan University	China
Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients NCT06592625 · ClinicalTrials.gov ↗ · Untreated Early-stage or Locally Advanced Breast Cancer	Phase 2	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression NCT07047443 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	Anhui Provincial Cancer Hospital	China
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study NCT07179939 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Not yet open	Fudan University	China
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer NCT07317778 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer NCT07466303 · ClinicalTrials.gov ↗ · Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer	Phase 2	Not yet open	Xijing Hospital	China
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases NCT07466927 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer	Phase 2	Not yet open	Fudan University	China
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. NCT07528898 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	Hebei Medical University Fourth Hospital	China
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients NCT07560475 · ClinicalTrials.gov ↗ · HER2positive, Advanced Breast Cancer, HER2 + Breast Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities NCT07630077 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Not yet open	Sun Yat-sen University	China
Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer NCT07630103 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Phase 2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer NCT07766772 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer, Advanced Breast Cancer	Phase 2	Not yet open	Fujian Cancer Hospital	China
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer NCT07776171 · ClinicalTrials.gov ↗ · Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)	Phase 2	Not yet open	Sun Yat-sen University	China
SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer NCT07787338 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Not yet open	First Affiliated Hospital of Zhejiang University	China
Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma NCT07802288 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy Failure NCT07817654 · ClinicalTrials.gov ↗ · GC, GEJC	Phase 2	Not yet open	Henan Cancer Hospital	China
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer NCT06990516 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Not yet open	Tongji Hospital	China
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane NCT05424835 · ClinicalTrials.gov ↗ · HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd.	China
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial NCT05814354 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd.	China
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy NCT06126640 · ClinicalTrials.gov ↗ · HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd.	China
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan NCT06199973 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Phase 3	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer NCT07196774 · ClinicalTrials.gov ↗ · Early-stage or Locally Advanced HER2-positive Breast Cancer	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd.	China
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing NCT05924256 · ClinicalTrials.gov ↗ · Advanced Salivary Gland Carcinoma	Phase 2	Active, closed	Fudan University	China
Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY） NCT05824325 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1/2	Active, closed	Fudan University	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Trastuzumab Rezetecan

57 conditions

Breast Cancer10 Advanced Breast Cancer5 Ovarian Cancer5 HER2-positive Breast Cancer4 HER2-negative Breast Cancer3HER2 + Breast Cancer3Solid Tumor2Recurrent or Metastatic Cervical Cancer2Breast Neoplasm2HR Positive/HER2 Low Breast Cancer2Biliary Tract Neoplasms Immunotherapy2PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer1

All 57 conditions

Condition (as registered)	Trials
Breast Cancer	10
Advanced Breast Cancer	5
Ovarian Cancer	5
HER2-positive Breast Cancer	4
HER2-negative Breast Cancer	3
HER2 + Breast Cancer	3
Solid Tumor	2
Recurrent or Metastatic Cervical Cancer	2
Breast Neoplasm	2
HR Positive/HER2 Low Breast Cancer	2
Biliary Tract Neoplasms Immunotherapy	2
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer	1
Advanced Gastric Cancer	1
Metastatic Gastric Cancer	1
Gastroesophageal Junction Adenocarcinoma	1
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy	1
Advanced Colorectal Cancer	1
Hormone Receptor Positive Tumor	1
Advanced Breast Cancer With Ultra-Low HER2 Expression	1
HER2positive	1
Advanced Salivary Gland Carcinoma	1
Gastric Cancer	1
Gastroesophageal-junction Cancer	1
Pancreatic Cancer	1
Breast Tumors	1
Triple-Negative Breast Cancer (TNBC)	1
Triple-negative Breast Cancer	1
Breast Cancer Early Stage Breast Cancer (Stage 1-3)	1
Early-stage or Locally Advanced HER2-positive Breast Cancer	1
Metastatic Breast Cancer	1
Triple Negative Breast Cancer (TNBC)	1
HER2-positive Early Breast Cancer	1
Breast Cancer Metastatic	1
Breast Cancer Brain Metastases	1
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane	1
Untreated Early-stage or Locally Advanced Breast Cancer	1
Platinum Sensitive Ovarian Cancer (PSOC)	1
HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer	1
Urachal Cancer	1
Advanced Solid Tumor Cancer	1
Antibody-drug Conjugates	1
Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer	1
HER2-positive Advanced Breast Cancer	1
Brain Metastases	1
Radiotherapy	1
GC	1
GEJC	1
Triple Negative Breast Cancer	1
HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis	1
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	1
Unresectable Locally Recurrent Breast Cancer	1
Unresectable Locally Metastatic Breast Cancer	1
UTUC	1
Urothelial Carcinoma	1
Advanced Urothelial Carcinoma	1
Urothelial Carcinoma Recurrent	1
Non Small Cell Lung Cancer	1

By country register

Register	Trials	Recruiting
Clinical trials in China	58	33

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Trastuzumab Rezetecan trials

How many clinical trials are testing Trastuzumab Rezetecan?

58 current trials in our China register name Trastuzumab Rezetecan (also registered as SHR-A1811) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Trastuzumab Rezetecan trials recruiting patients?

Yes. 33 of the 58 trials are recruiting: 33 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Trastuzumab Rezetecan clinical trials?

Fudan University (12), Suzhou Suncadia Biopharmaceuticals Co., Ltd (9), Jiangsu HengRui Medicine Co., Ltd (9) and Tianjin Medical University Cancer Institute and Hospital (3), among 22 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Trastuzumab Rezetecan works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Trastuzumab Rezetecan works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Trastuzumab Rezetecan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Trastuzumab Rezetecan clinical trials